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1. General information:– 
All reactions were performed in 100 mL stainless steel high pressure reactor. Reactions were 
monitored on Perkin Elmer Clarus 400 GC equipped with flame ionization detector (FID) 
with a capillary column (30 m × 0.25 mm × 0.25 μm) and TLC on Merck silica gel 60 F254 
plates visualized by UV lump at 254 nm. Products were purified by column chromatography 
on silica gel (120–200) mesh. All yields reported in Table 2 and Scheme 2 referred to isolated 
yields. While yields reported in Table 1 are GC yields. 1H and 13C NMR spectra were 
obtained on 400 and 500 MHz spectrometers using tetramethylsilane as internal standard in 
CDCl3. Chemical shifts of 
1H NMR and 13C NMR are reported as δ values relative to TMS 
and CDCl3 respectively. Chemical shifts were reported in parts per million (ppm, δ). Proton 
coupling patterns are described as singlet (s), doublet (d), triplet (t), quartet (q), and multiplet 
(m). Single-crystal diffraction analysis were obtained on BRUKER KAPPA APEX II CCD 
Duo diffractometer (operated at 1500 W power: 50 kV, 30 mA) at 100K using graphite-
monochromated Mo Kα radiation (λ = 0.71073 Å). More information on crystal structures 
can also be obtained from the Cambridge Crystallographic Data Centre, CCDC 1443655 for 
3s. Mass spectra were obtained on GC-MS-QP 2010 instrument (Rtx-17, 30 m × 25 mm ID, 
film thickness (df) = 0.25 µm) (column flow 2 mLmin-1, 80 °C to 240 °C at 10 °C/min rise). 
















2. General procedure for the synthesis of benzoxazinones (3a-3t) from anthranilic acid:  
 
To a 100 mL stainless steel high pressure reactor, anthranilic acid (1 mmol), aryl bromide 
(1.15 mmol), DABCO (2 mmol), PdCl2PhCN2 (3 mol %) and P(t-Bu)3·HBF4 (12 mol %) 
were added in 10 mL anhydrous toluene. The 400 mg activated 3 Å MS were added in the 
reaction mixture and the autoclave was closed. The autoclave was purged three times with 
carbon monoxide, pressurized with CO 200 psi at ambient temperature. The reaction mixture 
was stirred with a mechanical stirrer (500 rpm) at the 100 °C temperature for 24 h. After 
completion of reaction, the reactor was cooled to room temperature and the remaining CO 
was carefully vented. The reactor vessel was washed with ethyl acetate (3 × 10 mL) to 
remove traces of product, if present. The ethyl acetate layer was washed with water (2 × 10 
mL), dried over Na2SO4, and the solvent was evaporated under vacuum. The crude residue 
was purified by column chromatography  on  silica  gel  using  ethyl  acetate/petroleum ether  
as  eluents  to  give corresponding benzoxazinones.  
Representative analytical data of benzoxazinones: 
2-(4-methoxyphenyl)-4H-benzo[d][1,3]oxazin-4-one (3a) 1 
 
Isolated as a white solid 233 mg (92%); 1H NMR (400 MHz, CDCl3) δ 8.25 (d, J = 8.8 Hz, 
2H), 8.20 (d, J = 7.9 Hz, 1H), 7.79 (t, J = 7.6 Hz, 1H), 7.63 (d, J = 8.1 Hz, 1H), 7.46 (t, J = 
7.6 Hz, 1H), 6.98 (d, J = 8.8 Hz, 2H), 3.88 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 163.23, 
159.81, 157.09, 147.27, 136.50, 130.25, 128.53, 127.70, 126.88, 122.54, 116.66, 114.12, 
55.50. 
 
2-(2-methoxyphenyl)-4H-benzo[d][1,3]oxazin-4-one (3b) 1 
 
 
Isolated as a white solid 177 mg (70%);  1H NMR (500 MHz, CDCl3) δ 8.26 (dd, J = 7.8, 1.5 
Hz, 1H), 7.88 – 7.82 (m, 2H), 7.72 (d, J = 7.6 Hz, 1H), 7.56 – 7.50 (m, 2H), 7.09 – 7.03 (m, 
S4 
 
2H), 3.94 (s, 3H) 13C NMR (126 MHz, CDCl3) δ 159.8, 158.5, 157.7, 147.0, 136.4, 133.2, 
131.3, 128.4, 128.3, 127.2, 120.5, 120.5, 116.9, 112.1, 56.0. 
2-(p-tolyl)-4H-benzo[d][1,3]oxazin-4-one (3c) 2 
 
Isolated as a white solid 216 mg (91%); 1H NMR (CDCl3, 400 MHz):
 δ 8.23-8.18 (m, 3H), 
7.80 (t, J = 7.6 Hz, 1H), 7.66 (d, J = 8.0 Hz, 1H), 7.49 (t, J = 7.5 Hz, 1H), 7.30 (d, J = 7.9 Hz, 
2H), 2.43 (s, 3H); 13C NMR (CDCl3, 100 MHz): δ 159.7, 157.2, 147.1, 143.3, 136.4, 129.4, 
128.5, 128.2, 127.9, 127.4, 127.0, 116.9, 21.6. 
2-(p-tolyl)-4H-benzo[d][1,3]oxazin-4-one (3d) 3 
 
Isolated as a white solid 190 mg (80%); 1H NMR (500 MHz, CDCl3) δ 8.28 – 8.25 (m, 1H), 
8.04 (d, J = 7.9 Hz, 1H), 7.86 – 7.81 (m, 1H), 7.72 – 7.68 (m, 1H), 7.57 – 7.52 (m, 1H), 7.46 
– 7.41 (m, 1H), 7.36 – 7.31 (m, 2H), 2.74 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 159.7, 
158.3, 146.8, 139.1, 136.4, 131.9, 131.5, 130.1, 129.8, 128.4, 128.4, 127.2, 126.0, 116.7, 
22.2. 
 
2-(4-nitrophenyl)-4H-benzo[d][1,3]oxazin-4-one (3e) 4 
 
 
Isolated as a white solid 174 mg (65%);  1H NMR (500 MHz, CDCl3) δ 8.52 – 8.48 (m, 2H), 
8.39 – 8.34 (m, 2H), 8.30 – 8.26 (m, 1H), 7.92 – 7.87 (m, 1H), 7.77 – 7.74 (m, 1H), 7.63 – 
7.58 (m, 1H); 13C NMR (126 MHz, CDCl3) δ 158.7, 154.9, 150.1, 146.2, 136.9, 135.8, 129.3, 
129.2, 129.2, 128.8, 127.6, 123.8, 123.8, 117.1. 
 




Isolated as a white solid 161 mg (60%); 1H NMR (500 MHz, CDCl3) δ 9.04 (s, 1H), 8.51 (d, 
J = 7.8 Hz, 1H), 8.31 (d, J = 8.3 Hz, 1H), 8.15 (d, J = 7.9 Hz, 1H), 7.77 (t, J = 7.4 Hz, 1H), 
7.65 – 7.59 (m, 2H), 7.48 (t, J = 7.5 Hz, 1H). 




Isolated as a white solid 207 mg (86%);1H NMR (CDCl3, 400 MHz): δ 8.21 (d, J = 7.8 Hz, 
1H), 8.06 (d, J = 7.8 Hz, 1H), 7.97 (d, J = 8.0 Hz, 1H), 7.81 (t, J = 7.7 Hz, 1H), 7.66 (d, J = 
8.1 Hz, 1H), 7.56 – 7.41 (m, 2H), 7.29 – 7.20 (m, 1H); 13C NMR (CDCl3, 100 MHz): δ 164.0, 
161.5, 159.1, 155.8, 155.8, 146.5, 136.6, 132.4, 132.3, 130.3, 130.3, 128.6, 128.5, 127.3, 
123.9, 123.9, 119.7, 119.5, 116.9, 115.2, 115.0. 
methyl 4-(4-oxo-4H-benzo[d][1,3]oxazin-2-yl)benzoate (3h) 
 
 
Isolated as a white solid 253 mg (90%); 1H NMR (CDCl3, 400 MHz):
 δ 8.38 (d, J = 8.0 Hz, 
2H), 8.25 (d, J = 8.0 Hz, 1H), 8.16 (d, J = 8.0 Hz, 2H), 7.85 (t, J = 7.6 Hz, 1H), 7.72 (d, J = 
8.0 Hz, 1H), 7.55 (t, J = 7.6 Hz, 1H), 3.96 (s, 3H); 13C NMR (CDCl3, 100 MHz): δ 166.2, 
159.1, 156.5, 146.6, 136.8, 133.4, 129.8, 128.7, 128.6, 128.2, 127.4, 117.0, 114.5, 52.4. 
HRMS (ESI): calc. for [(C16H11NO4)H]
+ 282.0766, measured 282.0763. 
2-(4-(2,2,2-trifluoroacetyl)phenyl)-4H-benzo[d][1,3]oxazin-4-one (3i) 
 
Isolated as a white solid 230 mg (72%);1H NMR (CDCl3, 400 MHz):
 δ 8.46 (d, J = 8.8 Hz, 
2H), 8.25 (d, J = 8.0 Hz, 1H), 8.18 (d, J = 8.0 Hz, 2H), 7.86 (t, J = 7.6 Hz, 1H), 7.73 (d, J = 
8.0 Hz, 1H), 7.57 (t, J = 7.6 Hz, 1H); 13C NMR (CDCl3, 100 MHz): δ 180.5, 180.1, 179.7, 
179.4, 158.8, 155.2, 146.3, 136.8, 136.3, 132.4, 130.2, 130.2, 129.2, 128.7, 128.6, 127.6, 
117.8, 117.1, 115. 
HRMS (ESI): calc. for [(C16H8F3NO3)H]
+ 320.0535, measured 320.0529. 
4-(4-oxo-4H-benzo[d][1,3]oxazin-2-yl)benzonitrile (3j)  
 
Isolated as a white solid 206 mg (83%);1H NMR (CDCl3, 400 MHz):
 δ 8.39 (d, J = 8.2 Hz, 
2H), 8.24 (d, J = 7.7 Hz, 1H), 7.85 (t, J = 7.5 Hz, 1H), 7.78 (d, J = 8.2 Hz, 2H), 7.70 (d, J = 





Isolated as a white solid 240 mg (90%); 1H NMR (CDCl3, 400 MHz): δ 8.28 – 8.24 (m, 2H), 
7.89 – 7.85 (m, 1H), 7.72 (d, J = 8.1 Hz, 1H), 7.62 – 7.51 (m, 3H); 13C NMR (CDCl3, 100 
MHz): δ 162.0, 159.3, 158.4, 146.0, 136.8, 132.1, 129.5, 128.7, 127.9, 127.90, 127.7, 121.2, 
120.9, 117.0, 116.8, 116.6.  
HRMS (ESI): calc. for [(C15H7FN2O2)H]+ 267.0570, measured 267.0562. 
2-phenyl-4H-benzo[d][1,3]oxazin-4-one (3l) 3  
 
Isolated as a white solid 199 mg (89%);1H NMR (CDCl3, 400 MHz):
 δ δ 8.32 – 8.28 (m, 2H), 
8.23 (d, J = 7.9 Hz, 1H), 7.85 – 7.79 (m, 1H), 7.69 (d, J = 8.1 Hz, 1H), 7.59 – 7.54 (m, 1H), 
7.54 – 7.47 (m, 3H); 13C NMR (101 MHz, CDCl3) δ 159.5, 157, 146.9, 136.5, 132.5, 130.1, 
128.7, 128.5, 128.2, 128.2, 127.1, 116.9. 
2-(pyridin-4-yl)-4H-benzo[d][1,3]oxazin-4-one (3m) 5  
 
Isolated as a white solid 190 mg (85%); 1H NMR (CDCl3, 400 MHz):
 δ 9.49 (s, 1H), 8.77 (d, 
J = 3.6 Hz, 1H), 8.56 – 8.49 (m, 1H), 8.23 (d, J = 7.9 Hz, 1H), 7.84 (t, J = 7.7 Hz, 1H), 7.69 
(d, J = 8.1 Hz, 1H), 7.54 (t, J = 7.6 Hz, 1H), 7.47 – 7.40 (m, 1H); 13C NMR (CDCl3, 100 




Isolated as a white solid 192 mg (70%); 1H NMR (CDCl3, 500 MHz) δ 9.40 (s, 1H), 9.35 (s, 
1H), 9.21 (d, J = 8.7 Hz, 1H), 8.35 – 8.29 (m, 1H), 8.09 (d, J = 8.2 Hz, 1H), 7.95 – 7.87 (m, 
2H), 7.81 (d, J = 8.0 Hz, 1H), 7.76 – 7.70 (m, 1H), 7.63 – 7.58 (m, 1H); 13C NMR (CDCl3, 
125 MHz): δ 159.1, 156.5, 156.3, 146.5, 146.1, 136.7, 133.0, 132.3, 128.9, 128.6, 128.5, 
128.4, 127.8, 127.4, 125.1, 120.9, 117.1. 
HRMS (ESI): calc. for [(C17H10N2O2)H]





Isolated as a white solid 224 mg (90%);1H NMR (CDCl3, 400 MHz):δ 8.28 – 8.19 (m, 3H), 
7.80 (t, J = 7.6 Hz, 1H), 7.66 (d, J = 8.0 Hz, 1H), 7.55 – 7.44 (m, 3H), 6.76 (dd, J = 17.5, 
11.0 Hz, 1H), 5.88 (d, J = 17.6 Hz, 1H), 5.39 (d, J = 10.9 Hz, 1H); 13C NMR (CDCl3, 100 
MHz): δ 159.5, 156.8, 147, 141.6, 136.5, 135.9, 129.2, 128.5, 128.1, 127.1, 126.4, 116.9, 
116.5. 
HRMS (ESI): calc. for [(C15H11NO2)H]
+ 238.0868, measured 238.0862. 
2-(3-vinylphenyl)-4H-benzo[d][1,3]oxazin-4-one (3q) 
 
Isolated as a white solid 229 mg (92%);1H NMR (CDCl3, 400 MHz): δ 8.29 (s, 1H), 8.22 (d, 
J = 7.9 Hz, 1H), 8.17 (d, J = 7.7 Hz, 1H), 7.80 (t, J = 7.7 Hz, 1H), 7.67 (d, J = 8.0 Hz, 1H), 
7.59 (d, J = 7.6 Hz, 1H), 7.52 – 7.40 (m, 2H), 6.77 (dd, J = 17.6, 10.9 Hz, 1H), 5.87 (d, J = 
17.6 Hz, 1H), 5.34 (d, J = 10.9 Hz, 1H); 13C NMR (CDCl3, 100 MHz): δ 159.5, 156.9, 146.8, 
138.1, 136.5, 135.8, 130.4, 130.1, 128.9, 128.5, 128.2, 127.5, 127.1, 126.0, 116.9, 115.3. 
HRMS (ESI): calc. for [(C16H11NO2)H]
+ 250.0868, measured 250.0872. 
6,7-dimethoxy-2-phenyl-4H-benzo[d][1,3]oxazin-4-one (3q) 6 
 
Isolated as a white solid 238 mg (84%);1H NMR (CDCl3, 400 MHz): δ 8.27 (d, J = 7.8 Hz, 
2H), 7.57 – 7.46 (m, 4H), 7.11 (s, 1H), 4.03 (s, 3H), 3.99 (s, 3H); 13C NMR (CDCl3, 100 
MHz): δ 159.6, 156.7, 156.6, 149.8, 143.4, 132.4, 130.5, 128.8, 128.1, 109.7, 108.2, 107.7, 
56.68, 56.61. 
 




Isolated as a white solid 256 mg (86%);1H NMR (400 MHz, CDCl3) δ 8.09 (d, J = 8.0 Hz, 
2H), 7.48 (s, 1H), 7.25 (d, J = 8.0 Hz, 2H), 7.03 (s, 1H), 3.98 (s, 3H), 3.94 (s, 3H), 2.39 (s, 
3H); 13C NMR (100 MHz, CDCl3) δ 159.5, 156.7, 156.3, 149.4, 143.4, 142.9, 129.4, 127.9, 
127.5, 109.38, 107.8, 107.4, 56.4, 56.3, 21.6. 
6,7-difluoro-2-(p-tolyl)-4H-benzo[d][1,3]oxazin-4-one (3s) 
 
Isolated as a white solid 213 mg (78%);1H NMR (CDCl3, 400 MHz) δ  8.14 (d, J = 8.2 Hz, 
2H), 7.97 (t, J = 8.8 Hz, 1H), 7.47 – 7.42  (m, 1H), 7.30 (d, J = 8.1 Hz, 2H), 2.43 (s, 2H); 13C 
NMR (100 MHz, CDCl3) δ 158.0, 154.7, 152.4, 145.8, 143.9, 129.5, 128.3, 126.7, 116.3, 
116.2, 115.5, 115.3, 21.7. 
HRMS (ESI): calc. for [(C15H9F2NO2)H]
+ 274.0680, measured 274.0675. 
6-nitro-2-phenyl-4H-benzo[d][1,3]oxazin-4-one (3t) 8 
 
Isolated as a yellow solid 220 mg (82%);1H NMR (400 MHz, CDCl3) δ 8.48 (d, J = 9.0 Hz, 
2H), 8.34 (d, J = 9.0 Hz, 2H), 8.26 (d, J = 7.9 Hz, 1H), 7.87 (t, J = 7.7 Hz, 1H), 7.73 (d, J = 
8.1 Hz, 1H), 7.58 (t, J = 7.6 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 158.73, 154.90, 150.08, 
146.22, 136.91, 135.83, 129.33, , 128.80, 127.63, 123.87, 117.06. 
3. General procedure for the synthesis of quinazolinones (4a-4b) from anthranilic acid: 
 
 
To a 100 mL stainless steel high pressure reactor, anthranilic acid (1 mmol), aryl bromide 
(1.15 mmol), DABCO (2 mmol), PdCl2PhCN2 (4 mol %) and P(t-Bu)3·HBF4 (16 mol %) 
were added in 10 mL anhydrous toluene. The 400 mg activated 3 Å MS were added in the 
reaction mixture and the autoclave was closed. The autoclave was purged three times with 
S9 
 
carbon monoxide, pressurized with CO 200 psi at ambient temperature. The reaction mixture 
was stirred with a mechanical stirrer (500 rpm) at the 100 °C temperature for 24 h. After 
completion of reaction, the reactor was cooled to room temperature and the remaining CO 
was carefully vented. The corresponding amine were added in reaction mixture and further 
stirred for 12 h at 100 °C temperature. After completion of reaction, the reactor was cooled to 
room temperature. The reactor vessel was washed with ethyl acetate (3 × 5 mL) to remove 
traces of product, if present. The ethyl acetate layer was washed with water (2 × 5 mL), dried 
over Na2SO4, and the solvent was evaporated under vacuum. The crude residue was purified 
by column chromatography  on  silica  gel  using  ethyl  acetate/petroleum ether  as  eluents  
to  give corresponding quinazolinones. 
methyl 2-(4-oxo-2-phenylquinazolin-3(4H)-yl)propanoate (4b) 
 
Isolated as a yellow solid 246 mg (80%); 1H NMR (500 MHz, DMSO-d6) δ 8.63 (d, J = 8.3 
Hz, 1H), 7.93 – 7.85 (m, 3H), 7.66 – 7.53 (m, 4H), 7.22 (t, J = 7.6 Hz, 1H), 4.64 – 4.48 (m, 
1H), 3.36 (s, 3H), 1.42 (d, J = 7.2 Hz, 3H); 13C NMR (CDCl3, 125 MHz): δ 169.1, 161.4, 
147.3, 145.4, 134.9, 132.9, 132.5, 129.4, 129.0, 127.3, 123.3, 120.8, 120.5, 52.4, 48.8, 16.9. 
 
4. Experimental procedure for X-ray crystallographic analysis of compound 3o (CCDC 
1478766): 
The crystal of compound 3o (CCDC 1478766) was obtained by slow evaporation of the 
samples in dichloromethane and hexane. A suitable single crystal was mounted in a glass 
fibre, and diffraction measurements were taken with a diffractometer using graphite-
monochromated Mo Kα radiation (λ = 0.71073 Å). The structure was solved by direct 
methods using the programme SHELXS-1997 (Sheldrick, 2008). The refinement and all 




Identification code 3o 
Bond precision: C-C 0.0020 Å 
Chemical Formula C16H11NO2 
Formula Weight 249.26 
Temperature 100 K 
Wavelength 0.71073 
Crystal System monoclinic  
Crystal description Needle 
Crystal colour Colourless  
Space group P 21/n 
Unit cell dimensions  
a Å 12.255(9) 
b Å 3.849(3) 
c Å 25.380(16) 
α (°) 90 
β (°) 94, 92(2) 
γ (°) 90 
cell_volume 1192.8(15) 
Z  4 
Calculated density (mg/m3 ) 1.388 
Absorption coefficient (mm-1) 0.092 
F(000) 520 
Theta range for data collection ( )° 1.61 to 29.60 
Limiting indices -17<= h<=17, -5<=k<=5,- 35<=l<=35 
S11 
 
Reflection collected 3317 
Independent reflections 3367 [R int =0.0574] 
Absorption correction Multi scan 
Refinement method SHELXL-97 (Sheldrick, 2008) 
Data / restraints / parameters 3317/0/172 
Goodness-of-fit on F 2 1.012 
Final R indices [I>2sigma(I)] 0.0780 
R indices (all data) 0.0501 
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